Steve Sabus was named general manager of Astellas Pharma Canada (APCA), effective April 1, 2018. In his new role, he will lead business operations in the country.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Med Ad News asked its sources what are some of the key industry trends for 2018.
It’s not a new trend. For years, there has been massive speculation on the many ways Amazon could be getting into healthcare. But if you look past the hype, beyond Amazon’s theoretical intentions, and focus more closely on today’s consumer, there is a colossal healthcare trend underway even without Amazon getting in on the game. One can learn a lot from the trend of Amazon’s influence on the business of doing business. So let’s take a closer look …
According to the consultants at PwC, the top health industry issues of 2018 will be …
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
Robert Leverte Jr. was honored by the Medical Advertising Hall of Fame as its 2018 inductee on February 8 at a black-tie event at The Pierre Hotel in New York City. Leverte’s prolific career has included founding ERS – an in-house ad agency at ER Squibb – co-founding Ruvane-Leverte advertising, serving as chairman at Bozell Jacobs Medical Group, and operating as CEO of the Leverte Companies.
Uwe Röhrhoff was named CEO of Perrigo Company following the retirement of John T. Hendrickson.
Timothy Whitten has become president of Taiho Oncology Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co. Ltd. (Japan).
Christopher O’Brien, M.D., chief medical officer of Neurocrine Biosciences Inc., retired in February 2018 after a transition period with his successor.
Shaun Urban was named president of the Inception Companies.
Wayne Swanton was promoted to executive VP, Global Operations, at Allergan Plc following notification that Rob Stewart, executive VP and chief operating officer, intended to leave Allergan to become president and CEO of Amneal Pharmaceuticals.
Anu Balendran, Ph.D., was appointed VP Business Development at Alligator Bioscience.
Michael Mulhern joined AMRI as CEO, succeeding William S. Marth.
CVS Health introduced Transform Rheumatoid Arthritis Care to help the company’s pharmacy benefit management clients better manage care and costs for rheumatoid arthritis. The program is the latest addition to the company’s suite of condition-specific, highly personalized Transform Care programs and adds value-based management strategies including outcomes-based contracts and a new indication-based formulary for autoimmune conditions to CVS Health’s integrated pharmacy care model
As part of its CareCentered Contracting program, pharmacy benefit manager Prime Therapeutics LLC entered into an outcomes-based contract with Boehringer Ingelheim for Jardiance, an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.